Skip to main content
. 2022 Oct 10;48(6):207. doi: 10.3892/or.2022.8422

Figure 7.

Figure 7.

MiR-325-3p overexpression abrogates the effects of GPX2 in KRAS-mutated NSCLC cells. (A) A549 and NCIH1385 cells were introduced with GPX2, miR-325-3p or miR-ctrl lentivirus as indicated, and then lysates were collected for western blotting. (B) A549 and NCIH1385 cells (2,500/well) introduced with the indicated lentivirus were seeded in 96-well plates, and then cell viability was determined at days 0, 2, 4, and 6. (C-F) A549 and NCIH1385 cells introduced with indicated lentivirus were evaluated using (C, D) BrdU incorporation assays and (E, F) Transwell assays. Scale bar, 50 µm. (G) A549 and NCIH1385 cells (2,500/well) introduced with the indicated lentivirus were seeded in 96-well plates and treated with 0, 0.63, 1.25, 2.5, 5, 10, 20, 40, 80 and 160 µM cisplatin for 6 days, and then relative cell viability was evaluated by CCK-8 assay. *P<0.05. MiR-325-3p, microRNA-325-3p; GPX2, glutathione peroxidase 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; BrdU, bromodeoxyuridine; CCK-8, Cell Counting Kit-8.